Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.
Overview
to evaluate the wall-to-lumen ratio (WLR) of retinal arterioles in hypertensive patients with retinal vein occlusion (RVO) before and after dexamethasone intravitreal implant 0.7 mg (DEX) compared to a matched control group of normal eyes in non-hypertensive subjects.
Study Type
- Study Type: Interventional
- Study Design
- Intervention Model: Parallel Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: June 2012
Interventions
- Device: Dexamethasone Intravitreal Implant (Ozuredex)
Arms, Groups and Cohorts
- Active Comparator: Dexamethasone Intravitreal Implant
Clinical Trial Outcome Measures
Primary Measures
- change of outer arteriolar diameter
- Time Frame: the primary endpoint was at 6 months
- change of inner arteriolar diameter
- Time Frame: the primary endpoint was at 6 months
Secondary Measures
- Secondary outcome measures were as follows: adverse ocular events; mean change in visual acuity; and mean change in central macular thickness.
- Time Frame: Outcomes were analyzed at 4 intermediate time points: 30, 60, 90, and 150 days.
Participating in This Clinical Trial
Inclusion Criteria
- ability to provide written informed consent and comply with study assessments for the full duration of the study; – age > 20 years; – decreased visual acuity as a result of clinically detectable ME associated with either CRVO or BRVO; – the duration of macular edema was required to be between 4 and 24 weeks for both CRVO and BRVO; – retinal thickness in the central subfield (as measured using optical coherence tomography) had to be > 350 µm in the study eye. Exclusion Criteria:
- the exclusion criteria were as follows: diabetes; previous intravitreal anti-VEGF therapy or intravitreal steroid therapy; previous photodynamic therapy or focal laser; active retinal or optic disc neovascularization; active or history of choroidal neovascularization; presence of rubeosis iridis; any active infection; glaucoma, current ocular hypertension, or a history of steroid-induced intraocular pressure (IOP) increase in either eye; or concurrent eye disease in the study eye that could compromise visual acuity (e.g., choroidal neovascularization, diabetic retinopathy, epiretinal membrane).
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Università degli Studi di Brescia
- Provider of Information About this Clinical Study
- Principal Investigator: Andrea Russo, Dr. – Università degli Studi di Brescia
- Overall Official(s)
- Andrea Russo, Dr., Principal Investigator, University of Brescia, Italy
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.